Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

NCT03154515 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

445

Enrollment

INDUSTRY

Sponsor class

Conditions

Common Cold
Influenza, Human
Acute Respiratory Infection

Interventions

DRUG: Ingavirin
DRUG: Placebo

Sponsor

Valenta Pharm JSC